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Abstract 
Using multiparameter staining methods and flow cytomeyry to investigate the pluripotency of 
HUES7 human embryonic stem cell cultures it was found that the multidimensional approach 
of marker co-expression allowed the different cell populations to be easily identified and 
demonstrated cross reactivity between the SSEA 4 and SSEA 1 antibodies, resulting in a 
substantial false positive SSEA 1 population. It is the accepted norm to apply control gates at 
a 95% confidence level of the isotype control, however this study found that adjusting the 
control gate to a 99% confidence level significantly reduced the effect of this cross reactivity.  
Though conversely, this gating shift also decreased the positive marker expression of SSEA 4 
and Tra-1-60, indicating that there is a need for strongly expressing markers coupled with 
increased optimization of fluorophore/antibody combinations before a gating strategy of 99% 
can be implemented on a more routine basis.  
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Introduction 
Flow cytometry is a well-established, analytical technology employed across a wide range of 
medical and research areas to study the functional and structural properties of a cell. This is 
often accomplished by targeting protein markers with the application of fluorescently labeled 
monoclonal antibodies, both within and at the surface of the cytoplasmic membrane. 
Immunophenotyping is used extensively within hematology, and allows identification of 
multiple phenotypic and functional markers enabling the comprehensive interrogation of cells 
on a single cell level (Czechowska et al. 2008; Shapiro 1883). The advantage of flow 
cytometry is the combination of multiplexed assays; measuring several features of a single 
cell simultaneously, whilst sampling a statistically significant number of cells (~5000).  
 
The understanding of the biological and chemical processes that regulate a stem cells’ 
pluripotent and multipotent states would not have developed at the rate, and extent to which, it 
has, without flow cytometric analysis. Flow cytometry allows cells with any biologically 
interesting characteristics to be qualified and coupled with the application of fluorescence 
activated cell sorting (FACS), isolated. This at-line quality control testing and product 
purification while indispensable at laboratory scale will be critical in bringing clinical 
therapies to the market (Want et al. 2012).  
 
A number of human embryonic stem cell (hESC) pluripotency associated markers have been 
documented, both intracellular (e.g. transcription factors NANOG, SOX2 and OCT4 
(Chambers et al. 2003; Medvedev et al. 2008; Nichols et al. 1998; Adachi et al. 2010; Fong et 
al. 2008)) and surface (e.g. glycolipids SSEA 3/4, keratan sulfate antigens Tra-1-60 and Tra-
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1-81 (Draper et al. 2002; Wright and Andrews 2009; International Stem Cell Initiative 2007; 
Henderson et al. 2002)), however unlike their multipotent counterparts, mesenchymal stem 
cells (Dominici et al. 2006), no definitive phenotypic marker panel has been agreed upon 
(International Stem Cell Initiative 2007; Laslett et al. 2003; Carpenter et al. 2004). This is 
predominantly due to the fact that of the numerous embryonic cell lines that have been 
established (167 lines approved for use in UK alone (MRC UK Stem Cell Line Registry), for 
the limited number of these that have been compared at least, the expression levels for the 
reported pluripotency markers have been shown to be similar but not identical (International 
Stem Cell Initiative 2007; Carpenter et al. 2004). The contribution of divergent culture 
techniques in different laboratories to this diversity is debatable (Carpenter et al. 2004; 
Allegrucci et al. 2005; Allegrucci and Young 2007). Additionally, the lack of knowledge 
about documented target markers has also hindered the selection of a universal marker panel. 
This is particularly true for surface markers where for most, their physiological function 
remains unclear (Henderson et al. 2002; Allegrucci et al. 2005; Allegrucci and Young 2007) 
especially considering some are not exclusive to hESCs and are expressed on various other 
cell types (Allegrucci and Young 2007; Barraud et al. 2007; Linju-Yen et al. 2005; Gang et 
al. 2007). Still, given the potential of non-invasive FACS, surface markers are the ideal 
standard marker panel candidate.  Nevertheless, until such a time that a universal phenotypic 
marker panel is agreed upon, the current generally accepted minimum criteria for defining 
pluripotency of a hESC population is by demonstrating the expression of a combination of 
these markers (Hoffman and Carpenter 2005; Cai et al. 2006), usually with the addition of at 
least one known differentiation marker as a negative control. 
 
Current hESC literature is awash with flow cytometric data, but the vast majority employ 
laborious secondary (indirect) antibody methods, where a single fluorophore-conjugated 
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antibody is employed to detect all of the markers individually, or single color primary (direct) 
antibody staining where a fluorophore-conjugated antibody specific for the antigen of interest 
is applied. These conventional methods while effective in obtaining reliable and reproducible 
data are somewhat cumbersome and, more critically, information-poor in comparison to the 
capabilities of modern multiparameter flow cytometry. Multiparameter (a.k.a. multiplex or 
polychromatic) staining methods, apply a cocktail of fluorophore conjugated antibodies 
allowing multiple targets to be interrogated simultaneously, each indicated by a different 
fluorescent color. Pioneered in hematology laboratories in the 1980s (De Rossa et al. 2003), 
integration into stem cell laboratories has been relatively slow compared to other biological 
disciplines. Multiparameter flow cytometry is cost efficient, time saving and more robust, 
while requiring less sample volume than conventional staining methods (Prowse et al. 2009). 
Most crucially, it allows for the capture of multidimensional data (Jansen et al. 2008) which 
may otherwise have been left undisclosed. Multiparameter flow cytometry does, however, 
require a greater degree of understanding of the properties of fluorescent molecules and a 
greater variety of controls to ensure proper interpretation of data. This, in combination with 
limited availability of fluorophore-conjugated antibodies and the larger amount of post-
acquisition analysis has retarded the progression of multiparameter flow cytometry into stem 
cell research. These challenges are diminished however, by the ability of multiparameter flow 
cytometry to produce more information-rich datasets with the possibility of observing 
interactions between markers within a single cell. Currently, only a handful of stem cell 
focused publications (International Stem Cell Initiative 2007; Carpenter et al. 2004; 
Henderson et al. 2002; Gang et al. 2007; De Rossa et al. 2003; Prowse et al. 2009; Pruszak et 
al. 2007; Ramirez et al. 2011) have demonstrated the benefits of this technique but given the 
strength of the data these have presented, it is predicted that this number will continue to rise. 
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Here relatively simple three color multiparameter flow cytometry was employed to investigate 
the pluripotency of HUES7 hESC cultures. Three extracellular markers were chosen, due to 
their widespread use within hESC research SSEA 4, Tra-1-60 and SSEA 1. SSEA 1 which has 
been shown previously to be down regulated on pluripotent hESC and up regulated upon 
differentiation (Andews et al. 1996; Thomson et al. 1998) was included as a negative control. 
The main objective of this study was to illustrate the strength of multiparameter flow 
cytometry methods within stem cell research and how the acquired data can be exploited 
beyond the scope of the more conventional single color staining methods.  
Materials and Methods 
HUES7 cells were cultured feeder free on MatrigelTM basement matrix ((BD Biosciences) 
Thomas et al. 2009). Monolayer cultures were maintained in 5% CO2 37°C incubators 
between passages 24 and 36. Cells were passaged using 0.05% Trypsin/EDTA (Sigma 
Aldrich) for a 1 minute 37°C incubation followed by centrifugation for 5 minutes at 100g.  
 
All assay reagents and antibody conjugates were supplied as part of a surface antigen kit, 
FlowCellect Human ESC (Tra-1-60) Surface Marker Characterization Kit (Merck Millipore, 
Darmstadt, Germany). Briefly, single cell suspensions were prepared in wash buffer at a cell 
concentration of 1x106 cell/ml. 250µl cell suspension was transferred to each test sample tube 
before centrifugation at 600g for 3 minutes. Cells were resuspended in 500µl assay buffer and 
the centrifugation cycle repeated. After the supernatant was aspirated to waste, cells were 
resuspended in 100µl of assay buffer. Antibody (Tra-1-60-FITC, SSEA 4 -PE and SSEA 1-
PE/CY5) and negative control conjugates (IgM-FITC, IgG3-PE and IgM-PE/CY5) were 
applied (5µl per test) before being placed in a light proof container at 2-8°C for 1 hour. After 
incubation 400µl of assay buffer was added and test samples were centrifuged as before. Cells 
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were resuspended in a final volume of 500µl assay buffer and analyzed. Preliminary studies 
indicated that fixation of the cells had no impact on the assay (data not shown) so this step 
was omitted.   
 
All data were collected using a Guava easyCyte 8HT (equipped with 488 and 640 nm lasers); 
post-acquisition analysis was performed using FlowJo (v.7.6.5). Compensation adjustments 
were carried out at the time of analysis using IncyteTM acquisition software (v.2.2.2) on the 
analyzer. During post-acquisition analysis all compensation parameters were verified using 
the FlowJoTM compensation tool. A minimum of 5000 gated events per sample was collected. 
 
Throughout the study, cells were periodically karyotyped using standard G-banding of 30 
metaphase spreads at the Centre of Medical Genetics, Nottingham, UK. The samples were 
prepared according to the method described by Thomas et al. (2009). 
 
Results  
The multiparameter assay was conducted on 4 different HUES7 cultures, each at a different 
passage number; only two assays were subsequent passages of the same culture (Experiment 1 
at p34 and Experiment 2 at p36 culture). Cells were found to be karyotypically normal with a 
minimum of 28/30 nuclei analyzed having 46XY with no increase in abnormalities reported. 
Also, morphology of the cultures was consistent with pluripotent cells grown in monolayer.  
The expression levels of the extracellular markers (Figure 1) were indicative of a 
predominantly pluripotent culture, with each test sample strongly expressing SSEA 4 (≥96%) 
and, while Tra-1-60 was not as strongly expressed, the proportions shown here (≥ 60%) were 
similar to those reported elsewhere (Draper et al. 2002; Henderson et al. 2002). Figure 1(i) 
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clearly demonstrates the power of the multiparameter approach allowing for the quantification 
of the cell subpopulations that coexpress both positive target markers (SSEA 4 and Tra-1-60). 
Notably, almost all Tra-1-60 positive cells were SSEA-4 positive. Figure 1(ii) shows similar 
data expressing SSEA 4 against the negative marker expression SSEA 1, again the use of 
quadrants allowing the heterogeneous population to be clearly deciphered. The representative 
dot plot in Figure 1(ii) shows that approximately 15% of the cell population was expressing 
SSEA 1 however it was the positioning of this sub population on the SSEA 4 axis that was 
interesting, because it seemed that the SSEA 1 positive population  (median 13.3) was also 
emitting the strongest SSEA 4 intensity (median 421). On further analysis it was discovered 
that this was not an isolated event and was consistent throughout each test sample. This was 
particularly unexpected as it has previously been shown that upon differentiation, SSEA 4 is 
one of the first markers to be down regulated (International Stem Cell Initiative 2009; Liang 
et al. 2010). 
 
To explore this observation, the positive SSEA 1 population was backgated on to the SSEA 4 
Tra-1-60 dot plot (seen previously Figure 1(i)) to investigate where and how this sub 
population was distributed among the positive marker population. It was revealed that the 
SSEA 1 positive (SSEA 1+ve) population was preferentially distributed high in the double 
positive quadrant (Figure 2A). The scale of this preferential distribution cluster can be seen 
for each experiment in Figure 2B where the SSEA 1+ve population was isolated within SSEA 
4 Tra-1-60 quadrant gates to attain the percentage distribution. 
 
Figure 2B indicates that the SSEA 1+ve population is positioned at the upper limit SSEA 4+ve 
intensity. This combined with the low SSEA 1+ve fluorescence intensity, led to the hypothesis 
that this was the result of cross reactivity between the two glycolipid epitopes and not a true 
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SSEA 1+ve population. To test this the isotype control gate was expanded from 95% to 99%. 
(Figure 3A). The 4% adjustment had a significant effect, almost totally eradicating the SSEA 
1+ve population, which can be seen when comparing Q6 from Figure 1(iv) with Q6 in Figure 
3A(iv). This comparison can be seen even more clearly in Figure 3B which illustrates an 
example of the before and after backgated dot plot, where the SSEA 1+ve population was 
reduced from 15.4% to 2.9%. 
 
Conversely, while expanding the gates reduced the SSEA 1+ve population, the gating shift also 
reduced the positive population of the other two markers (SSEA 4+ve and Tra-1-60+ve; Table 
1). The decrease in the SSEA 4+ve was negligible with the majority of test samples retaining 
expression >95%, however Tra-1-60 expression, which in comparison was already relatively 
low, was considerably reduced with the shift. With expression levels lower than <45% the 
99% gate shift has inadvertently disqualified Tra-1-60 as a suitable hESC pluripotency marker 
for this cell line. To make such a conclusive assumption is beyond the scope of this work and 
will require a much more in depth study. However it is noteworthy that, when running 
successive passages (Exp. 1 and Exp. 2), a marked decrease in Tra-1-60 expression was 
observed over the 6 day culture period, shown in Table 1. Admittedly, SSEA 1 expression 
was also significantly decreased during this culture period although the high SSEA 1+ve 
population seen in Exp. 1 could be attributed to the aforementioned cross reactivity as on 
average it was reduced from 36% to <3% when the isotype gates were shifted to 99%. SSEA 
4 expression was not affected however, and remained constant >95% during this period, 
leading to uncertainties with regard Tra-1-60 expression stability and by extension, further 
question the suitability of this marker in the panel. 
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Discussion  
Multiparameter flow cytometry offers an enormous opportunity to greatly improve the quality 
and quantity of available data acquired from stem cell analysis. In this present study hESC 
cultures were investigated for expression of known pluripotency surface markers using a 
simple 3 color assay. The benefits compared to more conventional secondary or single color 
primary staining protocols were evident almost immediately. It was calculated that per 
multiparameter experiment where 8 tubes (1 isotype control, 3 compensation controls and 4 
multicolor test samples) were prepared, at least 15 tubes (3 isotype controls and 12 one color 
test samples) would be required to obtain the same level of repeatability if using conventional 
methods. This method instantly reduced preparation times, sample size requirements and 
costs. The inclusion of compensation controls in these initial assay development experiments 
meant significant savings of antibody volumes were not achieved. However, it was found that 
the compensation parameters for these experiments was very consistent with only very slight 
inter-assay adjustment being required (+/- 0.06 < 3%; data not shown) suggesting perhaps that 
once a stable protocol has been established, a single run of compensation controls could be 
used for future experiments. This is particularly true considering any inter assay variation 
could be corrected using post-acquisition analysis software. Removing these controls from 
some experiments at least, would decrease operator workload by 75% per experiment over 
conventional methods not to mention the increased cost efficiency. 
Furthermore, the capacity of additional data output when using multiparameter flow 
cytometry was enormously beneficial. The multidimensional aspect of marker co-expression 
was most useful in deciphering the different cell populations and demonstrated that there may 
be some cross reactivity between the SSEA 4 and SSEA 1 epitopes. This was an unexpected 
discovery and one that would have been impossible to deduce from conventional staining 
methods.  After a comprehensive review of the recent publications that have reported 
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multiparameter flow cytometry methods, surprisingly few have employed SSEA 1 as a 
negative marker, despite its frequent use in publications that applied conventional staining 
techniques. As a consequence, similar evidence of this potential cross reactivity does not seem 
to have been reported, though Strain et al. (2009) did report finding staining in markers with 
≤10% of cells above the isotype threshold was most often due to nonspecific binding, and 
additionally recommended increasing the isotype gates to ensure such events were gated out. 
The populations measured by flow cytometry can be approximately modeled by a normal 
distribution: this means that confidence intervals can be utilized that encompass a given 
proportion of the population. Gating the negative isotype control at a 95% confidence level 
literally applies a vertical delimiter defining any population to the left of this point as negative 
with 95% probability. Similarly, to the right is deemed a positive population. Current 
literature is replete with articles where the data has been gated at 95% of the negative control. 
however this study shows sufficient evidence that this is inadvisable, especially when the 
implication of such false positives in cells destined for the therapeutic market is considered, 
some of the samples investigated in this study presented with SSEA 1+ve population of up to 
35%, potentially leading to massive product and therefore potential financial losses.  On the 
other hand, if the isotype gates were to be shifted to 99%, then to ensure the utmost 
confidence in the data, there is a need for strongly expressing markers coupled with increased 
optimization of fluorophore antibody combinations. Otherwise, there is the risk that target 
populations will be gated out, again potentially leading to marked financial losses. The 
consequence of this can be seen in the Tra-1-60 marker expression which was effectively 
gated out when the isotype gate was increased to 99%. The average level of positive 
expression seen in this study (>60%) when gated at 95% of the isotype control are in line with 
values reported elsewhere in the literature (Draper et al. 2002; Henderson et al. 2002). 
However more interestingly, it has been shown that Tra-1-60 expression is particularly 
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sensitive to the cell culture conditions (Schinzel et al. 2011) and demonstrated how, by using 
different culture platforms, the Tra-1-60 expression could be increased or decreased 
accordingly. This in mind, it is difficult not to consider the possibility that under different 
culture conditions the recorded loss of expression between passages may have been greatly 
reduced if not totally eradicated and similarly the gate shift to 99% may not have been so 
detrimental to the marker expression in general. This paper lends weight to the opinions of 
Allegrucci and Young (2007) and the International Stem Cell Initiative (2007), that the 
regulation and standardization of human embryonic culture conditions among research 
laboratories could be the first steps required to limit expression marker variation in embryonic 
cell lines. Perhaps also by extension the first steps towards defining a universal phenotypic 
marker panel for human embryonic stem cells. 
 
Defining and fully understanding the characterization of pluripotent stem cells remains a 
major challenge in stem cell biology. Nevertheless, the considerable progress that has been 
documented to date strongly suggests that this is not an insurmountable task and with time 
this goal will be achieved. However for this to materialize, it will be imperative that 
researchers fully exploit current technologies and laboratory protocols to maximize the depth 
of all available data.  Multiparameter flow cytometry is a powerful cell characterization 
technique that maximizes the capture of significantly more data than conventional flow 
cytometry methods. This technique has a multitude of benefits to offer current and future stem 
cell research with available data increasing geometrically with the addition of each parameter 
(Preffer and Dombkowski 2009). It promises practically limitless potential, with considerable 
scope remaining for the introduction of new more advanced antibody conjugates to address 
the fundamental questions that are being raised as the regulatory establishment that controls 
pluripotent cell states is further elucidated. The application of multiparameter flow cytometry 
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in stem cell research is still in its infancy but recent publications (International Stem Cell 
Initiative 2007; Carpenter et al. 2004; Gang et al. 2007; De Rosa et al. 2003; Prowse et al. 
2009; Pruszak et al. 2007; Ramirez et al. 2011) suggest this technique is actively being 
incorporated into stem cell laboratories worldwide, representing hopefully the first important 
steps towards ensuring high resolution data-rich experiments become the accepted norm. 
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Figure and Table Legends 
Figure 1 – Cell Distribution at 95% Isotype Control Gate (i) and (ii) representative dot plots 
for the three markers, (i) SSEA 4/PE against Tra-1-60/FITC and (ii) SSEA 4/PE against 
SSEA 1/ PE-CY5. Each dot plot is flanked by two histograms highlighting the positioning of 
the quadrant boundaries corresponding to 95% of the isotype control. (iii) and (iv) bar charts 
are used to represent a specific quadrant on the density plot, with each bar showing the mean 
of the samples within a single experiment (error bars are calculated from the standard error).  
n ≥ 3 in all cases.  
 
Figure 2 - SSEA 1+ve Population Distribution (A) The isolated positive SSEA 1 population, 
shown here in the single color histogram was backgated onto the SSEA 4 Tra-1-60 dot plot. 
Backgating illustrated SSEA 1+ve population preferentially distributed high in the double 
positive quadrant Q2. (red black dot plot, where the red is the SSEA 1 positive population). 
Note slight increase in positive percentage from 15.2% on figure 1(ii) to 18.9% on 
histogram due to fact quadrant dot plot is gated at 95% of two colors and not just single 
color as in the case of the histogram. (B) The positive SSEA 1 population was isolated 
within the SSEA 4 Tra-1-60 quadrant gates to identify the percentage distribution of this 
daughter population for each sample. The percentage distribution is displayed on a bar chart 
next to the parent SSEA 4 Tra-1-60 population distribution.  
 
Figure 3 - Cell Distribution at 99% Isotype Control Gate (A) (i) and (ii) show representative dot 
plots for the three markers, (i) SSEA 4/PE against Tra-1-60/FITC and (ii) SSEA 4/PE against 
SSEA 1/ PE-CY5. Each dot plot is flanked by two histograms highlighting the positioning of 
the quadrant boundaries corresponding to 99% of the isotype control. (iii) and (iv) bar charts 
are used to represent a specific quadrant on the density plot, with each bar showing the mean of 
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the samples within a single experiment (error bars are calculated from the standard error).  n ≥ 
3 in all cases. (B) Illustrates a representative backgated dot plot before and after the gate shift. 
(i) shows the distribution of the SSEA 1+ve population at 95% of the isotype control on the left 
(shown previously in Figure 2) and (ii) on the right shows same population after the isotype 
control gate has been increased to 99%.  
.  
Table 1.  Expression (%) of surface markers recorded at 95% and 99% gating. The column 
immediately following the marker title column (2nd from left) highlights the single color 
expression levels for each marker. A loss of Tra-1-60+ve expression was observed between 
subsequent cultures (76.5 – 55.0%). Cells were in culture 6 days between analyses. 
Multiparameter marker co-expression can be read by cross referencing the marker title (column 
1) against the markers titled within the multiparameter column. Values given are the mean of 
the samples within a single experiment (± are calculated from the standard error) for each run, 
n ≥ 3 in all cases. 
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Table 1 
% Expression 
  
 
Single Parameter 
Data 
 
 
Multiparameter Data 
 
95% 
 
99% 
SSEA 4 Tra-1-60 
95% 99% 95% 99% 95% 99% 95% 99% 
+ve -ve +ve -ve 
 
 
Exp 1 
(n=3) 
SSEA 4 +ve 97.5±1.5 81.9±10.7         
SSEA 4 -ve 3.2±1.2 18.1±10.7         
Tra-1-60 +ve 75.6±4.0 42.1±5.2 73.1±3.3 34.4±0.6 2.5±0.1 7.8±5.7     
Tra-1-60 -ve 25.3±4.4 2.6±1.2 24.6±4.8 47.5±10.2 0.7±0.4 10.3±5.1     
SSEA 1 +ve 36.1±9.0 2.6±1.2 35.9±9.1 2.5±1.3 0.2±0.1 0.1±0.0 31.8±4.9 4.8±1.9 10.8±4.4 1.8±1.4 
SSEA 1 -ve 63.8±9.0 97.4±1.2 61.6±8.5 80.2±9.6 2.28±1.6 17.2±10.3 33.0±6.9 43.2±6.2 24.3±4.4 50.4±4.6 
 
 
Exp 2 
(n=4) 
SSEA 4 +ve 98.5±0.1 96.3±0.3         
SSEA 4 -ve 1.5±0.1 3.7±0.3         
Tra-1-60 +ve 55.0±1.8 25.9±1.4 54.7±1.8 25.6±1.4 0.2±0.1 0.3±0.1     
Tra-1-60 -ve 45.0±1.8 74.1±1.4 43.8±1.9 70.7±1.6 1.2±0.1 3.4±0.2     
SSEA 1 +ve 6.9±0.2 1.3±0.1 6.7±0.24 1.2±0.1 0.2±0.0 0.1±0.0 5.8±0.3 0.9±0.1 0.64±0.0 0.3±0.0 
SSEA 1 -ve 93.0±0.2 98.7±0.1 92.1±0.2 95.8±0.2 0.9±0.1 2.9±0.3 46.5±1.9 22.9±1.4 47.0±1.8 75.9±1.4 
 
 
Exp 3 
(n=4) 
SSEA 4 +ve 99.8±0.1 98.2±0.2         
SSEA 4 -ve 0.2±0.0 1.7±0.2         
Tra-1-60 +ve 79.2±0.9 42.3±1.5 79.2±0.9 42.2±1.5 0.1±0.0 0.1±0.0     
Tra-1-60 -ve 20.8±0.9 57.7±1.5 20.7±0.9 56.1±1.3 0.2±0.0 1.6±0.2     
SSEA 1 +ve 14.6±0.6 2.7±0.1 14.6±0.6 1.2±0.1 0.0±0.0 0.0±0.0 8.91±0.2 2.1±0.1 0.74±0.1 0.8±0.1 
SSEA 1 -ve 85.4±0.6 97.3±0.1 85.2±0.6 95.8±0.2 0.2±0.0 1.6±0.2 69.1±1.1 33.9±1.4 21.1±0.9 63.3±1.3 
 
 
Exp 4 
(n=4) 
SSEA 4 +ve 98.9±0.1 89.5±0.5         
SSEA 4 -ve 1.1±0.1 10.5±0.5         
Tra-1-60 +ve 57.6±1.4 29.8±1.5 57.5±1.4 28.8±1.4 0.1±0.0 1.0±0.1     
Tra-1-60 -ve 42.3±1.4 70.2±1.5 41.3±1.4 60.7±1.4 1.0±0.1 9.5±0.5     
SSEA 1 +ve 17.4±1.9 1.8±0.4 17.1±1.8 1.7±0.4 0.3±0.1 0.1±0.0 11.5±0.9 1.2±0.2 7.7±1.2 0.7±0.2 
SSEA 1 -ve 82.6±1.9 98.2±0.4 81.5±1.8 87.8±0.5 1.1±0.1 10.4±0.5 39.2±0.6 23.5±1.5 41.6±2.8 74.5±1.3 
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Figures 
 
 
Figure 1  
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Figure 2  
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Figure 3  
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Supplementary Figures 
 
 
Supplementary Figure 1.  Representative single color histograms demonstrating the Tra-1-60+ve 
expression of two successive passages, p34 (Exp. 1) and p36 (Exp. 2) where there was a 
significant reduction in positive expression. Cells were in culture 6 days between analyses.  
 
 
 
 
 
